J&J Medical Connect
TECVAYLI®

(teclistamab-cqyv)

+ Save link
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TECVAYLI® (teclistamab-cqyv)

Medical Information

TECVAYLI - Use of Closed System Transfer Devices in Clinical Trials

Last Updated: 08/06/2025

SUMMARY  

  • Closed system transfer devices (CSTDs) and other needleless connectors could be used in the preparation and/or administration of TECVAYLI.1
  • The proper use of CSTDs, including accounting for holdup volume and residual transfer volumes of CSTD components, is the responsibility of preparers and administrators.1
  • CSTD manufacturer guidance and site practice must be followed to ensure an accurate dose is prepared and delivered.1

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 06 August 2025.

 

References

Show
1 Data on File. Investigational Product Preparation and Administration Instructions for Subcutaneous Administration of 10 mg/mL and 90 mg/mL Teclistamab (JNJ-64007957) by Weight Based Dosing in mg/kg. TV-TEC-208759; version 6.0; 2024.